David Robertson, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1659378560
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,183,782 of the $1,378,301 with a category attached, or 85.9%. 60 manufacturers reported payments, led by Lilly USA, LLC at 41.1% of the total. Reporting peaked in 2019 at $391,650 and has fallen 51.6% since, to $189,577 in 2025. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,671 payments — averaging $516.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$567K
- AstraZeneca$341K
- Novo Nordisk$242K
- Boehringer Ingelheim$58K
- Acella Pharmaceuticals, LLC$56K
- Amgen$31K
- plus $84K from 54 others
Across 167 payments — averaging $2000.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$182K
- Bayer$44K
- F. Hoffmann-la Roche AG$35K
- Roche Diagnostics Operations, Inc.$30K
- Novo Nordisk AS$15K
- Harmony Biosciences LLC$13K
- plus $14K from 2 others
What the payments were for
- Consulting fees$54,7774%
- Speaking & faculty fees$1,183,78286%
- Travel & lodging$101,9297%
- Food & beverage$37,2843%
- Education$5300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$318,101
- TRULICITY$209,231
- JARDIANCE$163,574
- Ozempic$122,403
- ZEPBOUND$121,118
- MOUNJARO$93,166
- RYBELSUS$81,519
- NP Thyroid 60$56,428
- TZIELD$28,538
- Repatha$28,207
- Kerendia$13,912
- Tresiba$11,294
- CYCLOSET$8,618
- RECORLEV$2,450
- Korlym$2,323
- EYLEA$1,550
- t:slim X2 insulin pump$1,350
- t-slim insulin pump$1,300
- DC ACCU-CHEK Diabetes Management Solutions, Cables, Software, Kits and Accessori$760
- RAYOS$579
How this compares
$1,378,301 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 202 | $346,183 |
| TrulicityDulaglutide | 165 | $263,641 |
| MounjaroTirzepatide | 173 | $242,067 |
| JardianceEmpagliflozin | 151 | $189,875 |
| SomavertPegvisomant | 12 | $147,850 |
| FarxigaDapagliflozin Propanediol | 92 | $109,462 |
| GenotropinSomatropin | 56 | $101,096 |
| Norditropin FlexproSomatropin | 35 | $90,804 |
| RybelsusSemaglutide | 31 | $71,169 |
| TymlosAbaloparatide | 21 | $53,523 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 32 | $42,748 |
| Tresiba Flextouch U-100Insulin Degludec | 43 | $35,273 |
| SynthroidLevothyroxine Sodium | 384 | $33,527 |
| TradjentaLinagliptin | 36 | $27,425 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $22,553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $566,764 | $513,578360 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $241,528 | $424,247251 claims |
| Boehringer IngelheimJardiance, Tradjenta | $57,820 | $217,300187 claims |
| AstraZenecaFarxiga | $340,662 | $109,46292 claims |
| Radius Health, Inc.Tymlos | $294 | $53,52321 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $29,716 | $42,74832 claims |
| AbbVieSynthroid | $317 | $33,527384 claims |
| MerckJanuvia | $97 | $21,73622 claims |
| Johnson & JohnsonXarelto | $158 | $18,42612 claims |
| BayerKerendia | $14,351 | $16,59212 claims |
| Astellas Pharma US IncMyrbetriq | $59 | $10,71617 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $487 | $6,407579 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$1.5M
- Jonathan OwnbyAtlanta$291K
- Gulliermo UmpierrezAtlanta$63K
- Francisco PasquelAtlanta$40K
- Norman WelchAtlanta$25K
- Rachel DerrAtlanta$18K
- Kate WheelerAtlanta$17K
- John ZoraAtlanta$16K
- Ernest BeasleyAtlanta$14K
- Era ShahAtlanta$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.